With the replacement of QLT Inc. CEO Julia Levy by Paul Hastings, the company is trading a science-based talent for an executive who has built his career on marketing and sales. The change announced last week marks a natural pattern of maturing biotech companies that have reached profitability. But Hastings said the focus on building a sales force won't be at the expense of developing new therapies.

Levy told BioCentury that QLT (QLTI; TSE:QLT, Vancouver, B.C.) had been looking